Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REALYSE
NCT05035082Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2021
- Primary completion
- Jun 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05035082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035082.